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Some endocytic proteins have recently been shown to play a role in tumorigenesis. In this
study, we demonstrate that APPL2, an adapter protein with known endocytic functions, is
upregulated in 40% cases of glioblastoma multiforme, the most common and aggressive
cancer of the central nervous system. The silencing of APPL2 expression by small interfer-
ing RNAs (siRNAs) in glioma cells markedly reduces cell survival under conditions of low
growth factor availability and enhances apoptosis (measured by executor caspase activity).
Long-term depletion of APPL2 by short hairpin RNAs (shRNAs), under regular growth factor
availability, suppresses the cell transformation abilities, assessed by inhibited colony for-
mation in soft agar and by reduced xenograft tumor growth in vivo. At the molecular level,
the negative effect of APPL2 knockdown on cell survival is not due to the alterations in AKT
or GSK3b activities which were reported to be modulated by APPL proteins. Instead, we at-
tribute the reduced cell survival upon APPL2 depletion to the changes in gene expression,
in particular to the upregulation of apoptosis-related genes, such as UNC5B (a proapoptotic
dependence receptor) and HRK (harakiri, an activator of apoptosis, which antagonizes anti-
apoptotic function of Bcl2). In support of this notion, the loss of glioma cell survival upon
APPL2 knockdown can be rescued either by an excess of netrin-1, the prosurvival ligand of
UNC5B or by simultaneous silencing of HRK. Consistently, APPL2 overexpression reduces
expression of HRK and caspase activation in cells treated with apoptosis inducers, resulting
in the enhancement of cell viability. This prosurvival activity of APPL2 is independent of its
endosomal localization. Cumulatively, our data indicate that a high level of APPL2 protein
might enhance glioblastoma growth by maintaining low expression level of genes respon-
sible for cell death induction.
ª 2012 Federation of European Biochemical Societies.
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Recent discoveries indicate that some endocytic proteins are
involved in multiple steps of cellular signaling, not only by
participating in endocytosis of activated receptors, but also
by regulating the magnitude of signaling transmitted to the
cytoplasm, and further to the nucleus (Sorkin and von
Zastrow, 2009). Deregulation of cellular signaling can lead to
changes in gene transcription and may cause neoplastic
growth and tumorigenesis. Indeed, the involvement of many
endocytic proteins in the pathogenesis of cancer has been re-
ported (Mosesson et al., 2008; Pyrzynska et al., 2009). Two ho-
mologous proteins APPL1 and APPL2 (adapter proteins
containing pleckstrin homology domain, phosphotyrosine
binding domain and leucine zipper motif) represent good ex-
amples of proteins actively participating in both endocytosis
and cellular signaling (Banach-Orlowska et al., 2009;
Miaczynska et al., 2004; Rashid et al., 2009). In addition,
some lines of evidence suggest a possible role of these pro-
teins in cancer development and/or progression.
First, APPL proteins associate with several transmembrane
receptors and/or participate in their endocytic trafficking.
Among them are receptors for epidermal growth factoreEGF
(Jones et al., 2006; Lee et al., 2011; Miaczynska et al., 2004;
Zoncu et al., 2009), nerve growth factoreNGF (Lin et al., 2006;
Varsano et al., 2006), adiponectin (Mao et al., 2006), follicle-
stimulating hormoneeFSH (Dias et al., 2010; Nechamen
et al., 2004) and glutamate (Husi et al., 2000). Deregulation of
endocytosis and defective degradation of such receptors (in
particular receptor tyrosine kinases, RTKs) leads to sustained
signaling, changes in cell proliferation or transformation
(Haglund et al., 2007). Second, in some cell types APPL proteins
can enhance the activity of AKT, one of the key kinases in-
volved in the regulation of tumorigenesis. A high level of ac-
tive AKT increases cell proliferation, resistance to apoptosis
and to hypoxic conditions (Manning and Cantley, 2007).
APPL proteins interact with AKT1, AKT2, AKT3 (Mao et al.,
2006; Mitsuuchi et al., 1999; Nechamen et al., 2007; Saito
et al., 2007; Tan et al., 2010; Yang et al., 2003) and with several
components of the AKT signaling pathway, like p110 catalytic
subunit of phosphatidylinositol 3-kinase (PI3K) (Mitsuuchi
et al., 1999) and two major targets of AKT: GSK3b and TSC2
(Tan et al., 2010). Both APPL proteins appear to be required
for hepatocyte growth factor (HGF)-induced cell survival and
migration via activation of AKT (Tan et al., 2010). Third,
APPL proteins are able to translocate to the nucleus and inter-
act with the multiprotein complex NuRD (Miaczynska et al.,
2004) responsible for modifying chromatin by histone deace-
tylation and nucleosome remodeling. Overexpression of
APPL1 modulates the composition of NuRD complex contain-
ing class I histone deacetylase HDAC1 (Banach-Orlowska
et al., 2009). Class I HDACs have recently emerged as targets
for anti-cancer therapy (Weichert, 2009), however HDAC1
was also proposed as a marker for benign tumors and its
loss seems to be linked to enhanced tumor malignancy
(Lagger et al., 2010). Fourth, through interaction with Reptin
APPL proteins stimulate b-catenin-dependent transcription
(Rashid et al., 2009), which is known to be overactivated in dif-
ferent types of cancer (MacDonald et al., 2009). Finally, APPL1may also act as a proapoptotic factor by interacting with DCC
(deleted in colorectal cancer) and enhancing the DCC-induced
apoptosis in colorectal cancer cells (Liu et al., 2002).
Taking in consideration the facts mentioned above, we
investigated here a potential role of APPL proteins in the reg-
ulation of tumor growth. We chose glioma as a tumor model
because APPL proteins are abundantly expressed in the brain,
where they associate with AKT1 (Tan et al., 2010). Addition-
ally, The Cancer Genome Atlas (TCGA) Research Network
recently cataloged major genomic abnormalities in human
glioblastoma multiforme (GBM) samples (TCGA, 2008;
Verhaak et al., 2010). Many of them result in aberrations of sig-
naling molecules and pathways potentially regulated by APPL
proteins, like RTKs (mutational activation or amplification of
EGFR, PDGFRA and HGF receptor MET ) and AKT (inactivating
mutations and deletion of PTEN, activatingmutations of genes
encoding PI3K complex PIK3CA and PIK3R1, amplification of
AKT3), highlighting their importance for GBM development
and further supporting the choice of glioma as our experimen-
tal model.
We report here that the level of APPL2 protein is increased
in 40% cases of glioblastoma multiforme, when compared to
non-tumor brain tissue. Silencing of APPL2 leads to reduced
viability of glioma cell lines, their decreased transformation
abilities and impaired growth in vivo as xenografts. In line
with these findings, gene expression analysis upon APPL2 de-
pletion revealed a marked increase in expression of proapo-
ptotic HRK and UNC5B genes, which contribute to the
reduced cell survival.2. Materials and methods
2.1. Tissue, cell lines and transfections
Paraffin-embedded sections and snap frozen human non-
neoplastic brain tissue (obtained from seizure lobectomy)
and glioblastoma samples were kindly provided by the Brain
Tumour Tissue Bank (BTTB; London, Canada) and accompa-
nied with pathological reports. Each patient gave his/her writ-
ten informed consent on the use of the clinical specimens for
research. The study on human tumor samples was approved
by the Medical Advisory Committee of the BTTB. Human gli-
oma, epithelial (HeLa and A431) and colon cancer (HCT116
and DLD-1) cell lines were maintained in DMEM (Dulbecco’s
modified Eagle’s medium) supplemented with 5% fetal bovine
serum, L-glutamine (2mM), penicillin (100 units/ml) and strep-
tomycin (100 mg/ml). siRNA (7.5 nM) was delivered to LN229
cells using HiPerFect reagent (Qiagen), whereas U87MG cells
were transfected with 10 nM siRNA using SureFect reagent
(SABiosciences). For delivery of vectors and plasmids LN229
cells were transfected with FuGENE reagent (Roche),
U87MG cells with Lipofectamine LTX (Invitrogen) and T98G
cells with Lipofectamine 2000 (Invitrogen). All transfections
were performed according to manufacturers’ instructions.
2.2. siRNA, shRNA, vectors and lentiviral constructs
Four siRNAs against humanAPPL2were used, including twoHP
Genome Wide siRNAs from Qiagen, APPL2si #1 (cat. no:
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 6 7e8 4 69SI02652174) and APPL2si #2 (cat. no: SI02652188), as well as two
Silencer Pre-designed siRNAs from Ambion, APPL2si #3 (ID no:
26320) andAPPL2si #4 (ID no: 140524). Three siRNAs against hu-
man HRK (ID no: s194952, s194953, s194954) were purchased
from Ambion. The following negative control (non-targeting)
siRNAs were used: cat. no: 1022076 (Qiagen), cat. no: 4390843
and 4390846 (Ambion). For long-termsilencing theBlock-it Len-
tiviral RNAi Expression System (Invitrogen) was used together
with three custom target sequences: APPL2-sh #1, APPL2-sh
#2 and APPL2-sh #3 as well as control scrambled (scr.) se-
quences: APPL2-scr. #1, APPL2-scr. #2 and APPL2-scr #3 (Suppl.
Table 1). 293FT cell line was used for production of a replica-
tion-incompetent lentivirus that stably expresses the shRNA
of interest from the U6 RNAi cassette, followed by transduction
of LN229 cells. All procedures were performed according to
manufacturer’s instructions. The shRNA sequence targeting
lamin was used as positive control for lentiviral production
and LN229 cell transduction. LN229 cells were further treated
with3mg/mlblasticidinS (InvivoGen) for aweek, toobtain resis-
tant cell pools with constitutive APPL2 silencing.
In overexpression experiments, pcDNA3-based constructs
of untagged and N-terminally myc-tagged APPL2 were used.
The human HRK gene was synthesized (Epoch Biolabs) and
cloned in pcDNA3.1 vector (Invitrogen). 200 ng of purified plas-
mids were transfected per well of 96-well plate.
The point mutations were introduced into pcDNA3-myc-
APPL2 using QuikChange XL site-directed mutagenesis kit
(Stratagene) to generate N308D/M310K and K280E/Y283C/
G319R mutants which were verified by sequencing.
2.3. Immunohistochemical detection
For immunohistochemical staining of paraffin-embedded hu-
man glioblastoma specimens, sectioned at a thickness of
3 mm, the standardprotocol according toDAKO’s recommenda-
tions was used. The DAKO EnVision þ SystemeHRP, combined
with DAB þ Substrate-Chromogen, followed by hematoxylin
were employed. For pathological examination the sections
were stained only with hematoxylin and eosin (H&E).
2.4. Western blotting
Protein extracts from brain tissue and glioblastoma were pre-
pared by tissue homogenization in buffer containing 1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, 10mMTris (pH 8.0),
140mMNaCl andprotease inhibitor cocktail. LN229andU87MG
cellswere lysed in RIPA buffer containing 1%Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris (pH 7.4), 150 mM
NaCl, 0.5mMEDTAandprotease inhibitor cocktail. Protein con-
centration was measured with BCA Protein Assay Kit (Thermo
Scientific). Samples of 10e20 mg total protein were subjected
to SDS-PAGE. Resolved proteins were transferred to nitrocellu-
lose membrane (Whatman), probed with specific antibodies,
and detected with either enhanced chemiluminescence or Od-
yssey infrared imaging system (LI-COR Biosciences).
2.5. Antibodies
Polyclonal anti-APPL2 (Ab 1296) antibody against C-termi-
nal peptide was previously described (Miaczynska et al.,2004). Anti-APPL1 (Ab 5002) and anti-APPL2 (Ab 4567) anti-
bodies against C-terminal halves of proteins were raised
in rabbits (Eurogentech) and previously described (Rashid
et al., 2009). The information concerning other primary an-
tibodies used in Western blotting is included in Suppl.
Table 2. Secondary horseradish peroxidase-conjugated an-
tibodies were from Jackson ImmunoResearch, while sec-
ondary fluorophore-conjugated (IRDye 680 and IRDye
800CW) antibodies used in Odyssey system were from LI-
COR Biosciences.
2.6. Cell viability, BrdU incorporation and caspase 3/7
activity assays
Cells were seeded in 96-well plates (5000 cells per well in 100 ml
of medium) and transfected the next day. For the viability as-
say, the Cell Counting Kit-8 (CCK-8, SigmaeAldrich) was used.
CCK-8 solution (10 ml) was added to each well, incubated for
2 h at 37 C followed by absorbance measurement at 450 nm
(OD450). Five samples were measured per point and averaged.
The inhibitors of PI3K: LY294002 hydrochloride and wortman-
nin, as well as apoptosis inductors: retinoic acid p-hydroxya-
nilide (fenretinide, N-(4-hydroxyphenyl)retinamide, HPR),
ceramide C6 (N-hexanoyl-D-sphingosine) and inactive control
reagent dihydroceramide C6 were purchased from
SigmaeAldrich.
The BrdU incorporation rate was estimated with the Cell
Proliferation ELISA, BrdU (Roche). The cells were incubated
with BrdU for 5 h before fixing and staining with anti-BrdU-
POD followed by incubation with substrate solution and lumi-
nescence measurement.
For the caspase activity estimation, the Caspase-Glo 3/7
Assay (Promega) was used. 100 ml of the Caspase-Glo reagent
was added to eachwell, incubated for 1 h followed by lumines-
cence measurement. Five samples were measured per point
and averaged. The values corresponding to the caspase 3/7 ac-
tivity were normalized according to the cell number. Doxoru-
bicin (SigmaeAldrich) was used as a positive control for
caspase 3/7 activation. Human netrin-1 was purchased from
Axxora and used at concentration 150 ng/ml while human
EGF was purchased from PeproTech EC Ltd. and used at con-
centration 10 ng/ml.2.7. Soft agar assay
The 6-well plateswere first coveredwith bottom layer of 1% low-
melting point agarose (SigmaeAldrich), prepared in cell growth
medium. The cells (10,000 cells per well) were mixed with
0.33%agaroseandplatedonto thebottom layer. Theagarwas so-
lidified for 10min at 4 C and covered with 1ml of medium con-
taining10%serum.Cellswereculturedat37 Cfor3e4weeksand
supplemented once a week with the freshmedium.2.8. Animal studies
Five NOD-SCID mice per group were injected subcutaneously
with 5  106 glioma cells. The tumor growth was monitored
by measurement in 3e4 days intervals. After 1 month the an-
imals were sacrificed and the tumors were isolated and
Figure 1 e APPL2 protein is upregulated in human GBM samples. (A). Western blot analysis of APPL1, APPL2 (Ab 1296), Rab5, phospho-
EGFR, p53 as well as PTEN, in extracts from non-neoplastic (referred to as “non-tumor”) brain tissue and GBM samples. Level of GAPDH was
used as a loading control. (B). Quantification of APPL1, APPL2 and Rab5 levels in the samples shown in (A), using infrared imaging. For each
sample, the values corresponding to the intensity of bands were first normalized to the values corresponding to bands of GAPDH. Next, the values
corresponding to non-tumor samples were averaged and set as 1. Finally, the fold change for each sample was calculated versus the averaged value
mentioned above. (C). Statistical analysis of APPL2 protein level (quantified in panel B) in non-tumor and GBM samples (light tumor infiltrate
and tumor center) presented as a scatter plot. The mean value for non-tumor tissue group was set as 1. The p-values were estimated using
ManneWhitney test upon comparison of each group of GBM samples versus the group of non-tumor samples. (D). Immunohistochemical
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ical committee of the Medical College in Cracow.
2.9. Flow cytometry
Distribution of cells in the G1, S, and G2/M cell cycle phases
was measured based on propidium iodide (PI) staining using
standard flow cytometry method. The cells were fixed in
70% cold ethanol for 1 h, washed and incubated for 30 min
in 0.1% sodium citrate in PBS containing RNase (10 mg/ml)
and 50 mg/ml PI. Measurements were performed using FACS-
Calibur instrument (Becton Dickinson). Exactly 10,000 events
from each sample were collected in a single cell gate. Aggre-
gates and debris were excluded from the analyses by the cre-
ation of the gate on the FL2-W (transit time) versus FL2-A (total
cell fluorescence) cytogram according to the standard proce-
dure (http://www.ucl.ac.uk/wibr/services/docs/cellcyc.pdf).
The percentages of cells in the G1, S and G2/M phases were de-
termined based on the frequency distribution of DNA content
with CellQuest Pro software (Becton Dickinson).
2.10. Quantitative PCR
Cells were seeded in 6-well plates (300,000 cells per well) and
transfected the next day. Three days upon transfection total
RNA was isolated with High Pure Isolation Kit (Roche). For
cDNA synthesis random nonamers, oligo(dT)23 andM-MLV re-
verse transcriptase (SigmaeAldrich) were used according to
manufacturer’s instructions. For estimation of gene expres-
sion two types of StellARrays (Lonza) were used: Human Apo-
ptosis (cat. no: 00188295) and Human Cell Cycle Tox and
Cancer (cat. no: 00188299), each containing primer pairs for
detection of 94 genes of interest plus 2 controls. Quantitative
PCR was performed according to manufacturer’s recommen-
dations, using a 7900HT Fast Real-Time PCR thermocycler (Ap-
plied Biosystems). The GPR Data Analysis Tool (Lonza) was
used to estimate fold change of gene expression upon
APPL2 silencing versus control. For validation of gene
expression changes the TaqManR Assays (cat. no: 4448892, Ap-
plied Biosystems) were used. The PCR reaction was performed
with the TaqMan Gene Expression Master Mix (Applied
Biosystems).
For estimation of the expression of UNC5 and netrin family
members in LN229 and U87MG cells the specific primers were
designed using Primer Express 3.0 software (Applied Biosys-
tems; Suppl. Table 3). The PCR reaction was performed with
the Kapa Sybr Fast ABI Prism qPCR Kit (KapaBiosystems). For
estimation of DAPK1 and GAPDH expression the TaqManR As-
says were used (as described above). All final products were
analyzed on 1.5% agarose gels. As a negative control the re-
verse transcriptase was omitted during the standard cDNA
synthesis protocol. The expression values were obtained at
least in duplicate from 3 biological replicates. Relative quanti-
fication (RQ) method and Data Assist software (Applieddetection of APPL2 protein (Ab 4567) combined with H&E staining in sele
written in an upper left corner on every photo). Insets show higher magnific
the nucleus and in the cytoplasm; yellow arrows indicate cells lacking anti-A
bar [ 500 mm.Biosystems) were used to estimate fold change of gene expres-
sion upon APPL2 silencing (or overexpression) versus control.
The data were normalized according to the level of house-
keeping genes ACTB and GAPDH. Only samples with efficient
silencing (at least 70% reduction in APPL2 mRNA level) were
used in these experiments.
2.11. Immunofluorescence
HeLa cells grown on coverslipswere fixedwith 3%paraformal-
dehyde for 15 min, permeabilized and blocked in solution I
(0.1% saponine, 0.2% gelatin, 0.5% BSA in PBS) for 10 min at
room temperature. Washed coverslips were incubated with
primary antibodies diluted in solution II (0.01% saponine,
0.2% gelatin in PBS) for 1.5 h followed by incubationwith Alexa
Fluor-tagged secondary antibodies for 1 h. The coverslips were
washed and mounted onto glass slides using Mowiol (Sigma).
Images were acquired with laser-scanning confocal micro-
scope (Leica TCS SP2 AOBS) using a  63/1.4 numerical aper-
ture oil immersion objective.
2.12. Statistical analysis
The standard deviation is presented on the graphs as error
bars. The statistical significance was assessed by the Mann e
Whitney test. The p-values were marked with the asterisks on
the charts (*p < 0.05, **p < 0.01, ***p < 0.001).3. Results
3.1. Upregulation of APPL2 protein levels in human GBM
samples
To test the potential involvement of APPL proteins in growth or
progression of brain tumors,we first checked the level of APPL1
and APPL2 in protein extracts isolated from twenty five snap
frozen human GBM samples. Two types of samples (each ac-
companied by a pathological report) were analyzed: i) tissue
containing light tumor infiltrate and ii) samples from the tumor
center. Additionally, nine samples of non-neoplastic brain tis-
sue were used as controls. Semi-quantitative Western blotting
analysis using infrared imaging system revealed that APPL2
level was upregulated in twelve GBM samples (over 40% of
cases), when compared to non-neoplastic tissue (referred to
as “non-tumor”, Fig. 1A,B). This upregulation (fold increase be-
tween 2 and 9) was present in both types of GBM samples: four
samples (out of seven) with light tumor infiltrate (cases no: 1, 2,
5, 6) and eight (out of eighteen) samples of tumor center (cases
no: 8, 10, 15, 23, 24 and to a lesser extent cases no: 12, 17, 20). As
shown in Fig. 1C, the mean fold change of APPL2 protein level
was significantly increased in light tumor infiltrate and in tu-
mor center groups (mean ¼ 2.02 and 2.55, respectively). The
higher level of APPL2 protein was noticeable in tumor samplescted samples of non-tumor tissue as well as GBM cases (case numbers
ation of images. White arrows mark cells with APPL2 present both in
PPL2 staining; black arrows mark endothelial cells. The yellow scale
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the recurrent origin of the tumors, the patient’s age or sex
(Suppl. Table 4), or with the level of proteins known to have al-
tered signaling in GBM, like EGFR or p53 (Fig. 1A). In contrast to
APPL2, the levels of homologous APPL1 protein or Rab5 protein
did not exceed two-fold up- or downregulation inGBMsamples
(Fig. 1A, B).
In order to examine the intracellular distribution of APPL2
protein in GBM samples, we performed immunohistochemi-
cal (IHC) staining (Fig. 1D). Analysis of the specimens from
non-tumor tissue revealed a population of cells (resembling
normal brain cells, white arrow in case no 3) with APPL2 pres-
ent both in the nucleus and in the cytoplasm, as well as a pop-
ulation of glial cells completely lacking anti-APPL2 staining
(yellow arrows). In the infiltrating tumor cells present in
GBM samples (cases no 1 and 2) the cell protrusions and nuclei
were strongly stained with anti-APPL2. Also the infiltrating
gemistocytic tumor cells in case no 6 (large cells of irregular
shape, white arrow) expressed high levels of APPL2. In con-
trast, endothelial cells surrounding the blood vessel (black ar-
rows) completely lacked APPL2 staining. Generally, all cases of
GBM with upregulated APPL2 levels detected by Western blot-
ting also showed strong IHC anti-APPL2 staining of tumor cells
present both in the tumor center and in the surrounding brain
tissue infiltrated by the tumor cells.
We also compared the mRNA expression levels of APPL2 in
normal brain and in cancer tissues using the publicly available
Oncomine database (www.oncomine.org). Global gene ex-
pression patterns in brain tumors of different WHO grades
were derived from two studies (Bredel et al., 2005; Sun et al.,
2006). According to them, the level of APPL2mRNAwas signif-
icantly upregulated in glial brain tumors of various histogen-
esis and grade, including GBM, oligodendroglioma (OD),
anaplastic astrocytoma (AA) and oligoastrocytoma (OA)
(Suppl. Fig. 1). No significant alterations in APPL1 mRNA level
were detected (not shown).3.2. Silencing of APPL2 expression in glioma cells
decreases their viability, anchorage-independent growth in
soft agar and tumor growth in vivo
Upregulation of APPL2 protein levels in over 40% of human
GBM samples could either actively contribute to tumor growth
or progression, or be a passive consequence of the transfor-
mation process. To discriminate between these twoFigure 2 e Silencing of APPL2 expression decreases cell viability, growth
APPL1, APPL2 (Ab 1296) and GAPDH in glioma, epithelial and colon ca
days upon transfection of glioma cell lines: LN229 and U87MG with differ
Growth curves of glioma cells (lower panels) upon transient silencing of A
chart) were used: HP Genome Wide siRNA and Silencer pre-designed siR
using the lentiviral system. Three shRNA sequences targeting APPL2 as w
Western blot analysis of APPL1, APPL2 and lamin A/C is shown on the
expression (APPL2-sh #1 and 2) as well as control cell pools (APPL2-scr. #1
colonies over 500 mm in diameter, formed after 4 weeks of growth in soft ag
of the biggest colonies are shown on the right (3 representative photos per
(APPL2-sh #2 and scrambled-sh #2) were injected subcutaneously into 5 m
tumor growth curve and final tumor weight after 1 month are shown on the
comparison of APPL2-sh with scrambled-sh and were marked with the astpossibilities we first measured the effect of APPL2 silencing
on the viability of tumor cells. We selected two glioma cell
lines, LN229 and U87MG with medium and high endogenous
APPL2 protein levels, respectively (comparing to the panel of
different cancer cell lines; Fig. 2A).
To silence APPL2 expressionwe took advantage of four siR-
NAs with the best silencing potential (estimated in prelimi-
nary experiments using Western blotting analysis, data not
shown). These siRNAs were chosen from two sources: HP Ge-
nome Wide siRNA collection from Qiagen and Silencer pre-
designed siRNAs from Ambion (Fig. 2B, C). We found the sta-
tistically significant reduction in the proliferation rate upon si-
lencing of APPL2 expressionwith each siRNA, in both cell lines
grown under low serum availability (blue curves versus black
(control) curves in Fig. 2B, C and Suppl. Table 5). Moreover,
in case of U87MG line this effect was also observed in cells
grown under regular serum concentration (Suppl. Fig. 2).
To test whether long-term silencing of APPL2 expression
can affect glioma cell growth we performed experiments
with a stringent anchorage-independent growth assay. We
took advantage of a lentiviral silencing system and designed
three shRNA sequences targeting APPL2 (Suppl. Table 1).
Upon lentiviral transduction we selected the pools of LN229
cells and estimated the efficiency of APPL2 silencing by West-
ern blotting (Fig. 2D, left top panel). Two pools with the best si-
lencing (APPL2-sh #1 and 2) were next tested in the soft agar
assay. The constitutive silencing of APPL2 expression indeed
affected the growth in soft agar and reduced the size of colo-
nies when compared to scrambled sequences (Fig. 2D, graph
and photographs).
The cell pools were also injected subcutaneously into NOD/
SCID mice and their growth was monitored during 1 month
(Fig. 2E, left chart). The statistically significant reduction in tu-
mor growth in vivo was observed for the cell pool with APPL2
silencing (APPL2-sh) starting from day 23 post injection. The
significant difference in the size of tumors formed from
APPL2-sh and control cells was also confirmed by the estima-
tion of tumor weight at day 30 post injection (Fig. 2E, right
chart). Cumulatively, these findings argue that depletion of
APPL2 reduces the transformation abilities of glioma cells.3.3. Knockdown of APPL2 induces apoptotic cell death
To check the proliferation rate and incidence of apoptosis
upon APPL2 silencing we measured the BrdU incorporationin soft agar and tumor growth in vivo. (A). Western blot analysis of
ncer cell lines. (B, C). Specificity and efficiency of APPL2 silencing 3
ent siRNAs targeting APPL2, shown by Western blot (upper panels).
PPL2 expression. Two sources of siRNA (marked on the top of each
NA. (D). Long-term silencing of APPL2 expression in LN229 cells
ell as non-targeting scramble (APPL-scr.) sequences were used. The
left upper panel. The cell pools with the best silencing of APPL2
and 2) were further tested in soft agar assay. The quantification of cell
ar is shown on the graph (left lower panel). The phase-contrast photos
each cell pool). The scale bar [ 200 mm (E). Pools of LN229 cells
ice and the growth of xenografts was measured during 1 month. The
left and right charts, respectively. The p-values were calculated upon
erisk (*p < 0.05).
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 6 7e8 474
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 6 7e8 4 75rate and caspase 3 and/or 7 activity in parallel with cell viabil-
ity (Fig. 3). In LN229 cells, the decrease in cell viability (Fig. 3A,
left chart) corresponded well to a significant increase in cas-
pase activity induced by three APPL2 siRNAs during 4 days
of silencing (Fig. 3A, right chart). Although some increase in
the proliferation rate, measured by BrdU incorporation, was
also detected (middle chart), most of these changes were not
statistically significant. As a positive control of apoptosis in-
duction, robust caspase 3/7 activation was induced by the
treatment of cells with 5 mM doxorubicin (DNA-damaging
drug; Fig. 3B). In U87MG cells all four siRNAs significantly in-
creased caspase 3/7 activity during 5 days upon APPL2 silenc-
ing (Fig. 3C, right chart). Again, doxorubicin was used as
control of apoptosis induction (Fig. 3D).
The cell death induction due to the silencing of APPL2 ex-
pressionwas further confirmed in LN229 cells by propidium io-
dide staining followed by cell cycle analysis by standard flow
cytometry. Indeed, upon APPL2 silencing there was a statisti-
cally significant increase in the percentage of cells in subG1
phase (corresponding to dead cells) (Fig. 3E, histograms in up-
per panel). Additionally, an increase in percentage of cells in S
phase was also observed (Fig. 3E, left chart in the lower panel),
which is in agreement with the results of BrdU incorporation
(Fig. 3A, middle chart). As control, the LN229 cells treated
with 10 mM cisplatinum (chemotherapy proapoptotic drug)
showed increase in both subG1 and S phase (Fig. 3E, right histo-
grams in the upper panel and right chart in the lower panel). In
summary, we demonstrated that in both glioma cell lines
knockdown of APPL2 decreases cell viability and induces acti-
vation of caspases followed by apoptotic cell death.
3.4. Cell death induction upon silencing of APPL2
expression is not due to changes in the activity of AKT or
GSK3b
To unravel themolecularmechanism responsible for themod-
ulation of glioma cell survival and apoptosis by APPL2, we first
examined the pattern of cellular signaling upon knockdown of
APPL2 in LN229 andU87MGcells under conditions of low serum
availability. AKT and GSK3b activity were previously reported
to be modulated by APPL proteins (Schenck et al., 2008) and to
affect cell survival or proliferation (Manning and Cantley,
2007). Although we noticed a decrease in the level of active
AKT (phospho-AKT) in LN229 cells at 3 and 4 days upon silenc-
ing of APPL2 expression, it was not consistent between differ-
ent siRNA used (Fig. 4A, left panel and Suppl. Fig. 3). The
changes in AKT activity were not visible in U87MG cells, whereFigure 3 e Silencing of APPL2 expression enhances caspase activity. (A). T
activity of caspase 3 and/or 7 (right chart) were estimated in parallel, 4 days
Fig. 2) under conditions of 0.5% serum. The averaged values for each cont
viability and the caspase 3/7 activity were estimated like in (A) upon treatm
(C). U87MG cells were transfected with APPL2 siRNAs for 5 days under
caspase 3/7 activity were assayed as in (A). (D). U87MG cells were treated w
assays, like in (B). (E). The cell cycle analysis of LN229 cells upon silencing o
of the cell cycle histograms (cells stained with propidium iodide) are shown
on the histogram gate. Additionally, two histograms corresponding to untrea
(cispl.) for 3 days are shown on the right. The averaged percentage of cells i
(AeE). The p-values were calculated upon comparison of each APPL2 siR
asterisks (*p < 0.05, **p < 0.01, ***p < 0.001).a very high basal level of phospho-AKT was detected and
remained unaltered upon APPL2 silencing (Fig. 4A, right panel
and Suppl. Fig. 3). No changes in phospho-GSK3b, phospho-
ERKor their total levelsweredetected inany cell line.Moreover,
the level of p53, a known regulator of apoptosis, remained un-
changed upon silencing of APPL2 expression.
To verify whether a modest inhibition of AKT could reduce
glioma cell survival, we treated LN229 and U87MG cells with
2.5 mM wortmannin or 1 mM LY294002. Even though these
treatments were effective (Fig. 4B), no significant changes in
cell viability were detected (Fig. 4C). In summary, we conclude
that the cell death induction upon silencing of APPL2 expres-
sion cannot be due to alterations in the activity of AKT or
GSK3b.
3.5. Knockdown of APPL2 enhances proapoptotic gene
expression
To further look for themechanism responsible formodulation
of glioma cell survival by APPL2, we examined the pattern of
expression of cell cycle- and apoptosis-related genes upon
knockdown of APPL2 protein in LN229 cells under conditions
of low serum availability, using two siRNAs (APPL2si #1 and
2). Initially we took advantage of the quantitative RT-PCR Stel-
lARray Gene Expression System (Lonza). We found that the
mRNA levels of three cell cycle-related genes (Fig. 5A) and
four apoptosis-related genes (Fig. 5B) as well as two genes in-
volved in both: cell cycle and apoptosis regulation (total nine
genes) were significantly elevated ( p-value < 0.05, fold
change > 1.5). Four significantly downregulated genes were
also identified in these experiments (Fig. 5A and B).
We validated these results in an independent set of sam-
ples with APPL2 silencing using all four previously mentioned
siRNAs. The validation was performed with TaqMan gene ex-
pression assays, consisting of a pre-designed probe and
primer pairs for E2F2, HRK, MYC, PTEN, UHRF1 and UNC5B
plus the control housekeeping genes ACTB and GAPDH, as
well as APPL1 and APPL2, to prove good silencing efficiency
and specificity of siRNAs targeting APPL2 (Fig. 5C). Among
the six selected genes, the most consistent change (obtained
with at least three out of four APPL2 siRNAs) was the upregu-
lation of HRK (an activator of apoptosis, which antagonizes
anti-apoptotic function of Bcl2) and UNC5B (a proapoptotic de-
pendence receptor for netrin-1) mRNA levels (Fig. 5C). Since
these proteins are known to regulate cell death, we hypothe-
sized that they may participate in the induction of apoptosis
upon APPL2 knockdown.he cell viability (left chart), BrdU incorporation (middle chart) and the
upon transfection of LN229 cells with APPL2 siRNAs (the same as in
rol siRNA were set as 1 and shown as the black bars. (B). The cell
ent of LN229 cells with 5 mM doxorubicin for 2 days under 5% serum.
low serum availability. The cell viability, BrdU incorporation and the
ith 10 mM doxorubicin for 2 days followed by viability and caspase 3/7
f APPL2 expression for 5 days under low serum availability. Examples
in the upper panel. The percentage of cells in subG1 phase is marked
ted LN229 cells in 5% serum and cells treated with 10 mM cisplatinum
n subG1, S and G2/M phases of cell cycle is presented (lower panels).
NA to the corresponding control siRNA and were marked with the
Figure 4 e Induction of cell death is not due to inhibition of AKT or GSK3b activity. (A). Western blot analysis of the levels of AKT, GSK3b,
ERK and p53 under conditions of low serum availability. Extracts from LN229 cells (left panel) and U87MG cells (right panel) upon silencing of
APPL2 expression were analyzed. Levels of GAPDH, b-actin, clathrin heavy chain (CHC) and EEA1 were used as loading controls. (B). Western
blot analysis of the levels of phospho-AKT (p-AKT) and total AKT upon treatment of LN229 cells with wortmannin (wortm., 2.5 or 5 mM) and
LY294002 (LY, 1 or 5 mM) for up to 4 days. (C). Viability of LN229 and U87MG cells was analyzed upon treatment with wortmannin or LY294002
for 4 days under conditions of low serum availability.
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contributes to the loss of cell survival upon silencing of
APPL2 expression
To verify the hypothesis about the possible participation of
the dependence receptor UNC5B in the loss of cell survival
upon knockdown of APPL2 level we first analyzed the expres-
sion of different members of UNC5 family (UNC5A, UNC5B,
UNC5C ), their ligands from the netrin family (NTN1, NTN3,
NTN4), another related dependence receptor DCC and thesignaling molecule of the UNC5B pathway DAPK1
(Guenebeaud et al., 2010). Almost all genes were expressed
in both LN229 and U87MG cells (Fig. 6A) except for NTN1 in
U87MG cells. We therefore concluded that the signaling path-
ways of the dependence receptors might be functional in both
glioma cell lines and UNC5B can be potentially responsible for
the loss of their survival upon silencing of APPL2 expression.
To verify this hypothesis further we measured the viability
of LN229 cells upon APPL2 silencing in the presence of the ex-
cess of netrin-1, the ligand for UNC5B which is known to
Figure 5 e Knockdown of APPL2 level changes expression of cell cycle- and apoptosis-related genes. (AeB). Three days upon knockdown of
APPL2 level with APPL2si #1 and 2 (the same siRNAs as in Fig. 2) the gene expression pattern was analyzed using qRT-PCR in LN229 cells
cultured under low serum conditions. Two types of pre-designed 96-well arrays were employed: cell cycle-related (panel A) and apoptosis-related
(panel B). Only genes with fold changes <L1.5 or >1.5 and p-values <0.05 were considered as significantly down- or upregulated and their
names are mentioned on the charts. (C). Expression of APPL1, APPL2, E2F2, HRK, MYC, PTEN, UHRF1 and UNC5B was validated by qRT-
PCR using the TaqMan gene expression assays in LN229 cells 3 days upon transfection with 4 different siRNAs targeting APPL2 and the
corresponding control siRNAs. The p-values were calculated upon comparison of each APPL2 siRNA to the corresponding control siRNA and the
significant p-values are marked with the asterisks (*p < 0.05, **p < 0.01).
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Figure 6 e Loss of glioma cell survival depends on the upregulation of HRK and UNC5B expression. (A). The products of RT-PCR reaction with
primers specific for HRK, dependence receptors (UNC5A, UNC5B, UNC5C, DCC ), netrin ligands (NTN1, NTN3, NTN4) and DAPK1 were
visualized on 1.5% agarose gel. As negative control the reverse transcriptase (RT) was omitted during cDNA synthesis (indicated as “-“). (B). The
viability of LN229 cells estimated 3 days upon APPL2 knockdown under limited serum availability (as in Fig. 3). Human netrin-1 (150 ng/ml) or
human EGF (10 ng/ml) was present in the culture medium where indicated by “D” (left and right chart, respectively). (C). The viability of LN229
(left chart) and U87MG cells (right chart) estimated either upon transfection with vector (pcDNA3) or upon overexpression of HRK. (D). The
viability of LN229 cells estimated upon double silencing of APPL2 (by APPL2si #1 or #4 at 7.5 nM) and HRK (by three independent siRNAs or
non-targeting siRNA as control, at 7.5 nM each) (left chart). The efficiency of HRK knockdown (right chart) was estimated by quantitative PCR
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Indeed, the presence of netrin-1 in the culture medium res-
cued the decrease of LN229 viability (Fig. 6B, left chart) upon
APPL2 silencing with three siRNAs shown before to induce
caspase 3/7 activity (Fig. 3A). In contrast, EGF, a known activa-
tor of the AKT pathway, did not prevent the loss of cell viabil-
ity upon APPL2 silencing (Fig. 6B, right chart). These data
indicate that the regulation of cell survival by APPL2 is at least
partially mediated by UNC5B, a conclusion further supported
by the fact that overexpression of UNC5B in LN229 (He et al.,
2011) and in U87MG cells (Tanikawa et al., 2003) was reported
to induce apoptotic cell death.
To study the potential involvement of the proapoptotic
protein HRK in the regulation of glioma cell survival we over-
expressed HRK in LN229 and U87MG cells and measured their
viability 3 days later (Fig. 6C). We observed that HRK has in-
deed a proapoptotic activity in both cell lines and that the in-
crease in its level is able to induce death of glioma cells.
Moreover, simultaneous silencing of APPL2 and HRK expres-
sion rescued the loss of cell viability upon transfection with
APPL2si #1 and #4 (Fig. 6D, left chart). These data point to
the involvement of HRK in death of glioma cells upon knock-
down of APPL2.
3.7. Endosomal localization of APPL2 is not required for
its prosurvival activity and regulation of HRK expression
To further confirm the functional relationship between APPL2
and HRK, we overexpressed APPL2 in T98G GBM cell line
which has low endogenous amounts of APPL2 protein
(Fig. 2A). In these cells, APPL2 overexpression potentiated
cell viability under low serum availability (Fig. 7A), as also ob-
served in LN229 cells (Suppl. Fig. 4). We further testedwhether
APPL2 overexpression increases viability of T98G cells treated
with two apoptosis inducers: retinoic acid p-hydroxyanilide
(HPR) and ceramide C6. HPR-induced apoptosis was previ-
ously characterized in GBM cell lines (Lytle et al., 2005), while
ceramide was shown to induce the expression of HRK gene
(Rizvi et al., 2011). We observed that high amounts of APPL2
protein potentiated resistance of cells to HPR- or ceramide-
induced apoptosis, as measured by increased cell viability
(Fig. 7B) and reduced activity of effector caspases (Fig. 7C).
To gain mechanistic insights into the observed cytoprotec-
tive effects, we tested whether the endosomal localization of
APPL2 is important for its prosurvival activity. To this end,
we constructed two mutants of APPL2, N308D/M310K and
K280E/Y283C/G319R, based on the known mutations in
APPL1 deficient in binding to Rab5 and thus not recruited to
endosomal membranes (Miaczynska et al., 2004; Zhu et al.,
2007). We verified that both mutants of APPL2 are indeed pre-
dominantly soluble in the cytoplasm and not localized on
endosomes, in contrast to the wild-type APPL2 (Fig. 8A). Inter-
estingly, both mutants upon overexpression were equally po-
tent in enhancing cell survival as the wild-type proteinand normalized versus GAPDH expression level. (BeD). The viability of c
corresponding control siRNA (set as 1), while the viability of cells overexp
alone. The p-values were calculated upon comparison of each APPL2 siRN
marked with the asterisks (*p < 0.05, **p < 0.01).(Fig. 8B). We further verified whether these cytoprotective ef-
fects of APPL2 overexpression correlated with decreased ex-
pression of HRK gene. Consistently, overexpression of the
wild-type or the mutants of APPL2 reduced HRK expression
under conditions of HPR- or ceramide-induced apoptosis
(Fig. 8C). Cumulatively, these data argue that the endosomal
localization of APPL2 is not required for its prosurvival activity
and regulation of HRK expression in glioma cells.4. Discussion
4.1. Influence of APPL2 expression on cell viability,
apoptosis resistance and transformation abilities of glioma
cells
Our results revealed that over 40% among 25 cases of human
GBM appear to have a high level of APPL2 protein but not
APPL1 when compared to non-tumor tissue. Importantly,
also in GBM samples containing light tumor infiltrate (the bor-
der region between non-tumor tissue and tumor center) the
level of APPL2 protein was significantly upregulated, although
the number of investigated samples (7 cases) was small. A
high level of APPL2 may contribute to the expansion of infil-
trating tumor cells and favor some neoplastic properties of
low-grade brain tumors, since increase of its mRNA level
was well noticeable in tumors of grade II and III (Sun et al.,
2006). Such properties include elevated proliferation rates
and resistance to apoptosis, ability to migrate and invade sur-
rounding tissue, but not so much microvascular proliferation
and angiogenesis, which are mainly the features of grade IV
tumors (Brat and Mapstone, 2003).
In a model of two glioma cell lines, we demonstrated that
silencing of APPL2 expression decreased their viability, apo-
ptosis resistance and transformation abilities. In LN229 cell
line, lower viability was evident only under limited serum
availability, while in case of U87MG cells, it was also visible
in regular serum concentration, however to a smaller extent.
Importantly, growth factors are likely to be limited in vivo in-
side the nervous system parenchyma, where the infiltrating
tumor cells have to survive and proliferate at high rate, thus
in vitro studies under low serum availability are of physiolog-
ical relevance. It is possible that in cultured LN229 cells the
abundance of serum growth factors can completely overcome
the need for the functional APPL2 protein to support cell via-
bility. Moreover, the two cell lines may have different require-
ments for survival and APPL2 silencing could affect the
signaling from growth factors that are more important for vi-
ability of U87MG than LN229 cells. In fact, the presence of dif-
ferent growth factor receptors on the plasma membrane of
these cell lines was estimated by the antibody arrays
(Stommel et al., 2007). U87MG appears to have detectable
levels of EGFR, PDGFRb, VEGFR2 and MET, while LN229 cells
carry AXL, EGFR, EPHA2, ERBB2 and ERBB3 on their surface.ells transfected with APPL2 siRNAs was normalized to the
ressing HRK was normalized to the values corresponding to vector
A to the corresponding control siRNA and the significant p-values are
Figure 7 e Overexpression of APPL2 protein enhances glioma cell survival and attenuates apoptosis. (A). Overexpression of untagged and myc-
tagged APPL2 in T98G cells under conditions of low serum availability (left panel; GAPDH used as loading control in Western blot). Cell
viability (right panel) was analyzed 3, 4 and 5 days after transfection. The averaged values corresponding to 2 empty vectors (pcDNA3 and
pcDNA3-myc) at a given time point were set as 1. (BeC) The cell viability (B) and the activity of caspase 3 and/or 7 (C) were estimated in parallel
upon transfection of T98G cells with empty vector or plasmid carrying myc-tagged APPL2. One day upon transfection cells were treated either
with 5 mM ceramide C6 (C6) or control dihydroceramide C6 (DH) (left panels), or with 2 mM HPR or DMSO (right panels) and analyzed 2 days
later. The values for empty vector were set as 1. (AeC). The p-values are marked with the asterisks (*p < 0.05, **p < 0.01).
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 6 7e8 480The effect of knockdownof APPL2 protein on decreased cell
viability was at least partially due to enhanced caspase activ-
ity and stimulated apoptosis. Our results support a hypothesis
that the high level of APPL2 protein in tumor cells may favortheir resistance to apoptosis under limited growth factor
availability. In accordance with our data, the study with anti-
sense morpholinos revealed that knockdown of APPL1 or
APPL2 triggered a massive apoptosis and resulted in
Figure 8 e Endosomal localization of APPL2 is not required for its prosurvival activity and regulation of HRK expression. (A). HeLa cells were
transfected with the myc-tagged wild type (WT) or mutants of APPL2 (N308D/M310K, K280E/Y283C/G319R) and stained with an anti-myc
antibody. Scale bar, 20 mm (B). Overexpression of myc-tagged wild type (WT) or mutants of APPL2 in T98G cells under conditions of low serum
availability (left panel; GAPDH used as loading control in Western blot). Cell viability (right panel) was analyzed 3 days after transfection. The
averaged values corresponding to 2 empty vectors (pcDNA3 and pcDNA3-myc) were set as 1. (C). Expression of HRK was estimated by qRT-PCR
in T98G cells transfected with the indicated constructs and treated either with 10 mM ceramide C6 (C6) or dihydroceramide C6 (DH) (left panel),
or with 2 mM HPR or DMSO (right panel) for 30 h. The p-values were calculated upon comparison of each overexpressed construct to the
corresponding empty vectors and were marked with the asterisks (**p < 0.01, ***p < 0.001).
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 6 7e8 4 81embryonic lethality of zebrafish (Schenck et al., 2008). Simi-
larly, knockdown of APPL1 in the Xenopus endoderm caused
strong apoptosis in endodermal organs (Wen et al., 2010). Sur-
prisingly, the embryonic development of mice was unaffectedby the lack of APPL1 gene (Tan et al., 2010). Unfortunately the
APPL2 knockout mice are not yet available to evaluate the role
of APPL2 in mammalian development. Instead, silencing of
APPL2 expression had no obvious effect on the viability of
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 6 7e8 482mouse embryonic fibroblasts under normal culture conditions
(Tan et al., 2010), similarly to our results in glioma LN229 cells.
Long-term silencing of APPL2 expression inhibited growth
in soft agar even under regular serum concentration, in both
investigated cell lines. The colony formation in soft agar re-
quires growth under stringent anchorage-independent condi-
tions and is considered to be the characteristic of transformed
cells. It is possible that the negative effect of silencing of APPL2
expression on growth in soft agar, as well as on tumor growth
in vivo, was exclusively dependent on the inhibition of cell pro-
liferation or enhancement of apoptosis. On the other hand,
the effect on growth in soft agar was observed in both cell
lines under regular serum concentration, raising the possibil-
ity that also other molecular mechanisms regulating
anchorage-independent growth (beside proliferation, survival
and apoptosis) can be affected by knockdown of APPL2
protein.
4.2. Mechanisms responsible for enhanced cell death
upon silencing of APPL2 expression
Our results demonstrating enhanced expression of proapo-
ptotic genes UNC5B and HRK upon knockdown of APPL2 pro-
tein (Fig. 5) support the hypothesis that APPL2 may play
a beneficial role in GBM development, through apoptosis pre-
vention. The defects in apoptosis signaling and the aug-
mented survival pathways are common features of GBM
(Krakstad and Chekenya, 2010).
UNC5B is a member of the dependence receptor family,
comprising transmembrane receptors that transduce prosur-
vival signals when engaged by a ligand, but emit proapoptotic
signals in its absence. The disruption of dependence
receptor signaling has been implicated in carcinogenesis
(Goldschneider and Mehlen, 2010). Netrin-1, the ligand for
UNC5B, is an axon guidance molecule that plays also a crucial
role during neuroblastoma development as well as in colorec-
tal and breast tumorigenesis, by regulating apoptosis (Delloye-
Bourgeois et al., 2009; Fitamant et al., 2008; Mazelin et al.,
2004). Different types of tumors and cancer cell lines display
autocrine production of netrin-1, thus blocking UNC5B-
induced apoptosis (Delloye-Bourgeois et al., 2009; Fitamant
et al., 2008). On the other hand, in some cell lines the overex-
pression of UNC5B is able to significantly enhance the apopto-
sis (Wang et al., 2009). One possible interpretation of our
findings envisages that the high level of UNC5B expression
upon knockdown of APPL2 protein could surpass the level of
netrin expression, resulting in the presence of ligand-free
UNC5B receptors transducing proapoptotic signals. Such pos-
sibility would be supported by our findings that the levels of
netrin-1 mRNA remained unchanged in LN229 cells upon
APPL2 depletion (data not shown) when the expression of
UNC5B gene was increased Fig. 5. In addition, the presence
of recombinant netrin-1 in the medium significantly blocked
the proapoptotic effect initiated by APPL2 silencing (Fig. 6B).
We cannot however exclude that the other UNC5 familymem-
bers may also contribute to apoptosis regulation in glioma
cells. Therefore, further systematic measurements of protein
levels of netrin ligands and UNC5 receptors upon modulation
of APPL2 protein amounts will be required to uncover the ex-
act relationship between APPL2 and UNC5 receptors.HRK is an apoptosis-facilitating protein, able to bind and in-
activate the anti-apoptotic partners Bcl2 and Bcl-x (Inohara
et al., 1997). Induction of HRK expression in neurons, primary
hematopoietic cells and immortalized cell lines takes place
upon deprivation of their requisite growth factors (Harris and
Johnson, 2001; Imaizumi et al., 1999; Sanz et al., 2000, 2001;
Wakabayashi et al., 2002). Sensory neurons from HRK knock-
out mice are less sensitive to apoptosis induced by NGF with-
drawal (Coultas et al., 2007), while transient overexpression
of Hrk induces cell death of sympathetic neurons (Harris and
Johnson, 2001; Imaizumi et al., 1999; Putcha et al., 2001). In
our experimentalmodel, the enhanced expression of HRK cor-
related with the decreased cell viability and accelerated cell
death.Moreover, overexpressionofAPPL2 reducedmRNA level
of HRK, concomitant with increased resistance of cells to apo-
ptosis, arguing that HRK abundance is an important factor
contributing to prosurvival effects of APPL2.
In summary, our data demonstrate for the first time an
upregulation of APPL2 protein in human tumor samples. We
show that modulation of APPL2 level in glioma cells changes
the expression of genes responsible for cell death induction,
HRK and UNC5B, suggesting one possible molecular mecha-
nism by which APPL2may enhance tumor cell growth and ap-
optosis resistance. Intriguingly, these activities appear
independent of endosomal localization of APPL2 and therefore
could bemediated by its nuclear or cytoplasmic, but not endo-
somal, binding partners. Among others, APPL proteins inter-
act with the nuclear proteins, such as nucleosome
remodeling and histone deacetylase complex NuRD (Banach-
Orlowska et al., 2009; Miaczynska et al., 2004) or the multi-
functional transcriptional regulator Reptin (Rashid et al.,
2009). In the cytoplasm, APPL1 binds TRAF2 adapter protein
which affects NF-kB-dependent transcription (Hupalowska
et al., 2012). It is possible that some of these known binding
partners may contribute to APPL2-mediated regulation of
UNC5B and HRK expression. Even though the precise molecu-
lar details of such regulation remain to be further studied, our
data support an emerging notion that some multifunctional
endocytic proteins may contribute to the regulation of gene
transcription as well as tumorigenesis.Author contributions
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